Delivering esophago-gastric cancer care during the COVID-19 pandemic in the United Kingdom: a surgical perspective.


Journal

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
ISSN: 1442-2050
Titre abrégé: Dis Esophagus
Pays: United States
ID NLM: 8809160

Informations de publication

Date de publication:
04 Sep 2020
Historique:
received: 15 06 2020
revised: 06 07 2020
accepted: 02 08 2020
pubmed: 21 8 2020
medline: 10 9 2020
entrez: 21 8 2020
Statut: ppublish

Résumé

The COVID-19 pandemic continues to have a significant impact on the provision of medical care. Planning to ensure there is capability to treat those that become ill with the virus has led to an almost complete moratorium on elective work. This study evaluates the impact of COVID-19 on cancer, in particular surgical intervention, in patients with esophago-gastric cancer at a high-volume tertiary center. All patients undergoing potential management for esophago-gastric cancer from 12 March to 22 May 2020 had their outcomes reviewed. Multi-disciplinary team (MDT) decisions, volume of cases, and outcomes following resection were evaluated. Overall 191 patients were discussed by the MDT, with a 12% fall from the same period in 2019, including a fall in new referrals from 120 to 83 (P = 0.0322). The majority of patients (80%) had no deviation from the pre-COVID-19 pathway. Sixteen patients had reduced staging investigations, 4 had potential changes to their treatment only, and 10 had a deviation from both investigation and potential treatment. Only one patient had palliation rather than potentially curative treatment. Overall 19 patients underwent surgical resection. Eight patients (41%) developed complications with two (11%) graded Clavien-Dindo 3 or greater. Two patients developed COVID-19 within a month of surgery, one spending 4 weeks in critical care due to respiratory complications; both recovered. Twelve patients underwent endoscopic resections with no complications. Care must be taken not to compromise cancer treatment and outcomes during the COVID-19 pandemic. Excellent results can be achieved through meticulous logistical planning, good communication, and maintaining high-level clinical care.

Sections du résumé

BACKGROUND BACKGROUND
The COVID-19 pandemic continues to have a significant impact on the provision of medical care. Planning to ensure there is capability to treat those that become ill with the virus has led to an almost complete moratorium on elective work. This study evaluates the impact of COVID-19 on cancer, in particular surgical intervention, in patients with esophago-gastric cancer at a high-volume tertiary center.
METHODS METHODS
All patients undergoing potential management for esophago-gastric cancer from 12 March to 22 May 2020 had their outcomes reviewed. Multi-disciplinary team (MDT) decisions, volume of cases, and outcomes following resection were evaluated.
RESULTS RESULTS
Overall 191 patients were discussed by the MDT, with a 12% fall from the same period in 2019, including a fall in new referrals from 120 to 83 (P = 0.0322). The majority of patients (80%) had no deviation from the pre-COVID-19 pathway. Sixteen patients had reduced staging investigations, 4 had potential changes to their treatment only, and 10 had a deviation from both investigation and potential treatment. Only one patient had palliation rather than potentially curative treatment. Overall 19 patients underwent surgical resection. Eight patients (41%) developed complications with two (11%) graded Clavien-Dindo 3 or greater. Two patients developed COVID-19 within a month of surgery, one spending 4 weeks in critical care due to respiratory complications; both recovered. Twelve patients underwent endoscopic resections with no complications.
CONCLUSION CONCLUSIONS
Care must be taken not to compromise cancer treatment and outcomes during the COVID-19 pandemic. Excellent results can be achieved through meticulous logistical planning, good communication, and maintaining high-level clinical care.

Identifiants

pubmed: 32816020
pii: 5894848
doi: 10.1093/dote/doaa091
pmc: PMC7454454
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

J Natl Compr Canc Netw. 2020 Mar 20;:1-4
pubmed: 32197238
Gastrointest Endosc. 2011 Jul;74(1):35-43
pubmed: 21704807
Lancet. 2020 Jul 4;396(10243):27-38
pubmed: 32479829
Ann Surg. 2018 Jan;267(1):94-98
pubmed: 27759620
Br J Surg. 2020 Jun;107(7):785-787
pubmed: 32191340
BJS Open. 2020 Feb;4(1):86-90
pubmed: 32011816
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Anaesthesia. 2017 Dec;72(12):1501-1507
pubmed: 28983904
Br J Surg. 2020 Sep;107(10):1250-1261
pubmed: 32350857
Lancet Oncol. 2020 Apr;21(4):e181
pubmed: 32142621
Br J Surg. 2020 Aug;107(9):1097-1103
pubmed: 32293715
Br J Surg. 2020 Oct;107(11):1406-1413
pubmed: 32363596
EClinicalMedicine. 2020 Apr 05;21:100331
pubmed: 32292899
Dis Esophagus. 2020 Jun 05;:
pubmed: 32500134
JAMA. 2020 Apr 28;323(16):1545-1546
pubmed: 32167538

Auteurs

S Wahed (S)

Northern Oesophago-Gastric Unit, Royal Victoria Infirmary, Newcastle upon Tyne, UK.

J Chmelo (J)

Northern Oesophago-Gastric Unit, Royal Victoria Infirmary, Newcastle upon Tyne, UK.

M Navidi (M)

Northern Oesophago-Gastric Unit, Royal Victoria Infirmary, Newcastle upon Tyne, UK.

N Hayes (N)

Northern Oesophago-Gastric Unit, Royal Victoria Infirmary, Newcastle upon Tyne, UK.

A W Phillips (AW)

Northern Oesophago-Gastric Unit, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
School of Medical Education, Newcastle University, Newcastle upon Tyne, UK.

A Immanuel (A)

Northern Oesophago-Gastric Unit, Royal Victoria Infirmary, Newcastle upon Tyne, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH